These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

409 related items for PubMed ID: 10811138

  • 1. Acquisition of chemoresistant phenotype by overexpression of the antiapoptotic gene testosterone-repressed prostate message-2 in prostate cancer xenograft models.
    Miyake H, Nelson C, Rennie PS, Gleave ME.
    Cancer Res; 2000 May 01; 60(9):2547-54. PubMed ID: 10811138
    [Abstract] [Full Text] [Related]

  • 2. Testosterone-repressed prostate message-2 is an antiapoptotic gene involved in progression to androgen independence in prostate cancer.
    Miyake H, Nelson C, Rennie PS, Gleave ME.
    Cancer Res; 2000 Jan 01; 60(1):170-6. PubMed ID: 10646870
    [Abstract] [Full Text] [Related]

  • 3. Antisense TRPM-2 oligodeoxynucleotides chemosensitize human androgen-independent PC-3 prostate cancer cells both in vitro and in vivo.
    Miyake H, Chi KN, Gleave ME.
    Clin Cancer Res; 2000 May 01; 6(5):1655-63. PubMed ID: 10815883
    [Abstract] [Full Text] [Related]

  • 4. Castration-induced up-regulation of insulin-like growth factor binding protein-5 potentiates insulin-like growth factor-I activity and accelerates progression to androgen independence in prostate cancer models.
    Miyake H, Pollak M, Gleave ME.
    Cancer Res; 2000 Jun 01; 60(11):3058-64. PubMed ID: 10850457
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Progression to androgen independence is delayed by adjuvant treatment with antisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model.
    Gleave M, Tolcher A, Miyake H, Nelson C, Brown B, Beraldi E, Goldie J.
    Clin Cancer Res; 1999 Oct 01; 5(10):2891-8. PubMed ID: 10537358
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Increased Hsp27 after androgen ablation facilitates androgen-independent progression in prostate cancer via signal transducers and activators of transcription 3-mediated suppression of apoptosis.
    Rocchi P, Beraldi E, Ettinger S, Fazli L, Vessella RL, Nelson C, Gleave M.
    Cancer Res; 2005 Dec 01; 65(23):11083-93. PubMed ID: 16322258
    [Abstract] [Full Text] [Related]

  • 12. Synergistic chemosensitization and inhibition of progression to androgen independence by antisense Bcl-2 oligodeoxynucleotide and paclitaxel in the LNCaP prostate tumor model.
    Leung S, Miyake H, Zellweger T, Tolcher A, Gleave ME.
    Int J Cancer; 2001 Mar 15; 91(6):846-50. PubMed ID: 11275990
    [Abstract] [Full Text] [Related]

  • 13. Antisense Bcl-2 oligodeoxynucleotides inhibit progression to androgen-independence after castration in the Shionogi tumor model.
    Miyake H, Tolcher A, Gleave ME.
    Cancer Res; 1999 Aug 15; 59(16):4030-4. PubMed ID: 10463603
    [Abstract] [Full Text] [Related]

  • 14. Timing is everything: preclinical evidence supporting simultaneous rather than sequential chemohormonal therapy for prostate cancer.
    Eigl BJ, Eggener SE, Baybik J, Ettinger S, Chi KN, Nelson C, Wang Z, Gleave ME.
    Clin Cancer Res; 2005 Jul 01; 11(13):4905-11. PubMed ID: 16000589
    [Abstract] [Full Text] [Related]

  • 15. Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancer.
    Rocchi P, So A, Kojima S, Signaevsky M, Beraldi E, Fazli L, Hurtado-Coll A, Yamanaka K, Gleave M.
    Cancer Res; 2004 Sep 15; 64(18):6595-602. PubMed ID: 15374973
    [Abstract] [Full Text] [Related]

  • 16. The suppression of human prostate tumor growth in mice by the intratumoral injection of a slow-release polymeric paste formulation of paclitaxel.
    Jackson JK, Gleave ME, Yago V, Beraldi E, Hunter WL, Burt HM.
    Cancer Res; 2000 Aug 01; 60(15):4146-51. PubMed ID: 10945622
    [Abstract] [Full Text] [Related]

  • 17. Inhibition of LNCaP prostate tumor growth in vivo by an antisense oligonucleotide directed against the human androgen receptor.
    Eder IE, Hoffmann J, Rogatsch H, Schäfer G, Zopf D, Bartsch G, Klocker H.
    Cancer Gene Ther; 2002 Feb 01; 9(2):117-25. PubMed ID: 11857028
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Antisense oligodeoxynucleotide therapy targeting clusterin gene for prostate cancer: Vancouver experience from discovery to clinic.
    Miyake H, Hara I, Gleave ME.
    Int J Urol; 2005 Sep 01; 12(9):785-94. PubMed ID: 16201973
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.